A private pharmaceutical company re-purposing an existing approved drug for a new indication. N-003 (ambrisentan) may be the first therapy for portal hypertension and its complications in patients with liver cirrhosis.

Location

Lange Gasse 15, 4052 Basel, Switzerland

Facts & figures
  • Type of organization

    Private company

  • Year of foundation

    2010

  • Number of employees in Switzerland

    1-9

Key business